OR WAIT null SECS
The investment, which is taking place in Hillerød, Denmark, will aim to create more production capacity and increase the company’s ability to meet future market demands and to continue development on its future clinical late-phase product portfolio.
Novo Nordisk announced on June 12, 2023, that the company plans to invest 15.9 billion Danish kroner starting in 2023 to further expand an existing API production facility in Denmark. The investment, which is taking place in Hillerød, Denmark, will aim to create more production capacity and increase the company’s ability to meet future market demands and to continue development on its future clinical late-phase product portfolio.
“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” said Henrik Wulff, executive vice president of Product Supply, Quality & IT, in a press release. “The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies—allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”
The 65,000-square-meter facility is going to be designed as a multi-product facility, with maximum flexibility to accommodate new processes and displaying state-of-the-art technology and working environment, according to the press release. Novo Nordisk will be designing optimal and compact process flows to allow a substantial reduction of water and energy consumption to accomplish this.
Novo Nordisk’s facility is expected to start producing API by early 2029, and it is hopeful to create 340 new jobs when construction is completed. The facility is also fully equipped.
Source: Novo Nordisk